The new declaration in the pharma industry of the United States

Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) today reported that the amended business organization concurrence with Aytu Bioscience ("Aytu") to quicken the development of NATESTO® in the United States is currently shut and completely viable as of December 1, 2019.

The two gatherings have commonly postponed the end states of the overhauled association understanding, including the necessity that Acerus comp....